ATE219363T1 - Lösliche prodrugs von paclitaxel - Google Patents
Lösliche prodrugs von paclitaxelInfo
- Publication number
- ATE219363T1 ATE219363T1 AT97932226T AT97932226T ATE219363T1 AT E219363 T1 ATE219363 T1 AT E219363T1 AT 97932226 T AT97932226 T AT 97932226T AT 97932226 T AT97932226 T AT 97932226T AT E219363 T1 ATE219363 T1 AT E219363T1
- Authority
- AT
- Austria
- Prior art keywords
- paclitaxel
- onium salts
- methods
- novel
- salts
- Prior art date
Links
- 229930012538 Paclitaxel Natural products 0.000 title abstract 5
- 229960001592 paclitaxel Drugs 0.000 title abstract 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 5
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1997/010746 WO1998058927A1 (en) | 1997-06-20 | 1997-06-20 | Soluble prodrugs of paclitaxel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE219363T1 true ATE219363T1 (de) | 2002-07-15 |
Family
ID=22261122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97932226T ATE219363T1 (de) | 1997-06-20 | 1997-06-20 | Lösliche prodrugs von paclitaxel |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1001769B1 (de) |
| JP (1) | JP2002505682A (de) |
| AT (1) | ATE219363T1 (de) |
| AU (1) | AU3574097A (de) |
| CA (1) | CA2294606A1 (de) |
| DE (1) | DE69713526D1 (de) |
| HU (1) | HUP0002521A3 (de) |
| IL (1) | IL133585A0 (de) |
| SK (1) | SK182599A3 (de) |
| WO (1) | WO1998058927A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003524624A (ja) * | 1999-04-09 | 2003-08-19 | ジェシー エル エス オウ | 治療薬の組織への送達を高める方法及び組成物 |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
| US6638906B1 (en) | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
| US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| MXPA03006404A (es) * | 2001-01-18 | 2004-12-02 | Upjohn Co | Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada. |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| JP2006524232A (ja) | 2003-03-17 | 2006-10-26 | アルバニー モレキュラー リサーチ インコーポレーティッド | 新規サイクロスポリン |
| JP2007525188A (ja) | 2003-05-16 | 2007-09-06 | インターミューン インコーポレイテッド | 合成ケモカイン受容体リガンドおよびその使用方法 |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| EP1804823A4 (de) | 2004-09-29 | 2010-06-09 | Amr Technology Inc | Neue cyclosporin-analoga und ihre pharmazeutischen anwendungen |
| JP2008514701A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | シクロスポリンアルキン類似体およびそれらの薬学的使用 |
| US7361636B2 (en) | 2004-10-06 | 2008-04-22 | Amr Technology, Inc. | Cyclosporin alkynes and their utility as pharmaceutical agents |
| WO2006089218A2 (en) | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating angiogenesis |
| AU2008272785B2 (en) | 2007-07-03 | 2014-06-12 | Children's Hospital & Research Center At Oakland | Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting |
| EP2296645B1 (de) | 2008-05-22 | 2014-11-19 | Galera Therapeutics, LLC | Antitumorale kombinationstherapie |
| WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
| US9359376B2 (en) * | 2011-04-08 | 2016-06-07 | Sphaera Pharma Pte. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| JP6578206B2 (ja) | 2012-07-19 | 2019-09-18 | レッドウッド バイオサイエンス， インコーポレイテッド | Ｃｄ２２に特異的な抗体およびその使用方法 |
| WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| SI3300745T1 (sl) | 2013-02-15 | 2020-01-31 | The Regents Of The University Of California | Himerni antigenski receptor in postopki njihove uporabe |
| WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| CN105744935B (zh) | 2013-11-27 | 2022-09-30 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
| WO2015127137A1 (en) | 2014-02-19 | 2015-08-27 | Aldea Pharmaceuticals, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
| WO2017083637A1 (en) | 2015-11-12 | 2017-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
| US20210206826A1 (en) | 2015-11-19 | 2021-07-08 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
| EP3231421A1 (de) | 2016-04-11 | 2017-10-18 | Greenaltech, S.L. | Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen |
| CN109071634A (zh) | 2016-04-26 | 2018-12-21 | R.P.谢勒技术有限责任公司 | 抗体偶联物及其制备和使用方法 |
| EP3463308B2 (de) | 2016-06-01 | 2026-01-07 | Servier IP UK Limited | Formulierungen von polyalkylen-oxid-asparaginase und verfahren zur herstellung und verwendung davon |
| KR102905343B1 (ko) | 2017-01-18 | 2025-12-29 | 바이오아트라, 인코퍼레이티드 | Axl 또는 ror2에 대한 키메라 항원 수용체 및 이의 사용 방법 |
| EP3388082A1 (de) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex |
| CN118652192A (zh) | 2017-05-24 | 2024-09-17 | 德克萨斯州大学系统董事会 | 用于抗体药物缀合物的接头 |
| IL276407B2 (en) | 2018-01-31 | 2025-01-01 | Galera Labs Llc | Combination cancer therapy with a pentase macrocyclic ring complex and a platinum-based anticancer agent |
| CA3095757A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating glioblastomas |
| EP3773632A4 (de) | 2018-04-06 | 2022-05-18 | The Regents of The University of California | Verfahren zur behandlung von egfrviii-exprimierenden glioblastomen |
| CN112368011A (zh) | 2018-04-11 | 2021-02-12 | 俄亥俄州创新基金会 | 缓释微粒用于眼用药物递送的方法和组合物 |
| MX2021000644A (es) | 2018-07-18 | 2021-08-19 | Manzanita Pharmaceuticals Inc | Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos. |
| BR112021019701A2 (pt) | 2019-04-02 | 2021-12-14 | Kenjockety Biotechnology Inc | Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos |
| BR112022013870A2 (pt) | 2020-01-29 | 2022-09-13 | Kenjockety Biotechnology Inc | Anticorpos anti-mdr1 e usos dos mesmos |
| WO2021247426A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
| EP4161564A1 (de) | 2020-06-04 | 2023-04-12 | Kenjockety Biotechnology, Inc. | Multispezifische antikörper gegen abcg2-effluxpumpen-krebsantigen und zusammensetzungen, reagenzien, kits und verfahren im zusammenhang damit |
| JP7747741B2 (ja) | 2020-09-02 | 2025-10-01 | ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 | 抗ａｂｃｃ１抗体及びその使用 |
| EP4244257A1 (de) | 2020-11-13 | 2023-09-20 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (codiert durch abcc4-gen) antikörper und verwendungen davon |
| MX2023005979A (es) | 2020-11-20 | 2023-08-11 | Scherer Technologies Llc R P | Enlazadores de escisión doble de glicósido para conjugados de anticuerpo y fármaco. |
| KR20240116829A (ko) | 2021-12-13 | 2024-07-30 | 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 | 항-abcb1 항체 |
| WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998053811A1 (en) * | 1997-05-27 | 1998-12-03 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| WO1997015571A1 (en) * | 1995-10-27 | 1997-05-01 | The Scripps Research Institute | Method for treating cancer using taxoid onium salt prodrugs |
-
1997
- 1997-06-20 SK SK1825-99A patent/SK182599A3/sk unknown
- 1997-06-20 AU AU35740/97A patent/AU3574097A/en not_active Abandoned
- 1997-06-20 HU HU0002521A patent/HUP0002521A3/hu unknown
- 1997-06-20 DE DE69713526T patent/DE69713526D1/de not_active Expired - Lifetime
- 1997-06-20 CA CA002294606A patent/CA2294606A1/en not_active Abandoned
- 1997-06-20 IL IL13358597A patent/IL133585A0/xx unknown
- 1997-06-20 AT AT97932226T patent/ATE219363T1/de not_active IP Right Cessation
- 1997-06-20 WO PCT/US1997/010746 patent/WO1998058927A1/en not_active Ceased
- 1997-06-20 JP JP50434699A patent/JP2002505682A/ja not_active Ceased
- 1997-06-20 EP EP97932226A patent/EP1001769B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2294606A1 (en) | 1998-12-30 |
| HUP0002521A2 (hu) | 2001-06-28 |
| SK182599A3 (en) | 2000-07-11 |
| EP1001769B1 (de) | 2002-06-19 |
| WO1998058927A1 (en) | 1998-12-30 |
| EP1001769A4 (de) | 2000-05-24 |
| DE69713526D1 (de) | 2002-07-25 |
| JP2002505682A (ja) | 2002-02-19 |
| AU3574097A (en) | 1999-01-04 |
| IL133585A0 (en) | 2001-04-30 |
| HUP0002521A3 (en) | 2002-04-29 |
| EP1001769A1 (de) | 2000-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| DK0975595T3 (da) | Kokainanaloger | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| DE50102490D1 (de) | Verwendung von substituierten imidazo [1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| DE69324466D1 (de) | L-dopa Ester-enthaltende Zusammensetzung | |
| ATE308327T1 (de) | Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs | |
| EP1024802A4 (de) | (3si(r), 4si(r))-sg(d)-tetrahydrocannabinolsäure als entzündungshemmern und analgesika | |
| UA34416C2 (uk) | Похідні хроману, активні стосовно 5-нт рецептора, спосіб їх одержання та проміжні сполуки | |
| TR200101163T2 (tr) | Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları | |
| GR80853B (en) | Kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical compositions suitable therefor | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| TR199801614T2 (xx) | Peptit t�revleri | |
| ES8400742A1 (es) | Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co. | |
| ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
| YU19302A (sh) | 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| YU17999A (sh) | Novi derivati pentaeritrita, njihova izrada i primena kao i međuproizvodi za njihovu sintezu | |
| YU25202A (sh) | Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera | |
| ATE275953T1 (de) | 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis | |
| MY126998A (en) | Substituted pyrroles. | |
| BR0016646A (pt) | Método para tratar um paciente que sofre de dor, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |